Skip to main navigation Skip to search Skip to main content

Health Equity, HPV and the Cervical Cancer Vaccine

    Research output: Contribution to journalArticlepeer-review

    Abstract

    This article explores the relationship between technological innovation and health inequity. It examines in particular the relationship between the vaccine against human papillomavirus (HPV) infection, the cause of cervical cancer, and inequity in cervical cancer incidence and mortality. In Canada, screening programs have drastically reduced the incidence of cervical cancer, but their benefits have been unequally distributed. Prevention efforts have disproportionately failed women of disadvantaged social groups. Technological innovation alone will not remedy this inequity. The HPV vaccine merely expands the available means for reducing or increasing health inequity depending on its implementation. For this reason, the article looks beyond technological innovation to focus on both the positive and negative health equity effects of the Canadian HPV vaccination strategy.

    Original languageCanadian English
    JournalArticles, Book Chapters, & Popular Press
    VolumeSpecial Edition
    Publication statusPublished - Jan. 1 2008

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being
    2. SDG 10 - Reduced Inequalities
      SDG 10 Reduced Inequalities

    Keywords

    • Health Law
    • Health Equity
    • Health Inequity
    • Vaccines
    • Bioethics
    • Cervical Cancer Vaccine
    • Human Papillomavirus Vaccine
    • Technological Innovation
    • Disproportionality

    Disciplines

    • Health Law and Policy
    • Law
    • Law and Gender
    • Medical Jurisprudence

    Fingerprint

    Dive into the research topics of 'Health Equity, HPV and the Cervical Cancer Vaccine'. Together they form a unique fingerprint.

    Cite this